Annals of Hematology

, Volume 64, Issue 1, pp 16–21 | Cite as

Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: A clinical and erythrokinetic assessment

  • G. E. G. Verhoef
  • P. Zachée
  • A. Ferrant
  • H. Demuynck
  • D. Selleslag
  • L. Van Hove
  • F. Deckers
  • M. A. Boogaerts
Original Article

Summary

The clinical and ferrokinetic effects of escalating doses of subcutaneously administered recombinant human erythropoietin (rh-EPO) were studied in ten patients with myelodysplastic syndromes and severe transfusion-dependent anemia. Red blood cell transfusion requirements diminished in four patients, and one of the patients eventually became transfusion independent with an EPO-induced rise of Hb from 7.7 g/dl to 12.3 g/dl. Endogenous serum levels of EPO were significantly increased in all patients (100–5700 mU/ml), but three of four responders had a relatively low baseline level. The effective red cell iron turnover (RCIT) improved in two responding patients and even normalized in one patient. This increase in RCIT was accompanied with a decline in the ineffective red cell iron turnover (IIT). The other responding patients had a relatively preserved RCIT before EPO treatment. EPO therapy further increased the fraction of IIT in the latter patients. Red cell survival time did not increase during EPO therapy, even in the responding patients. One transient and one maintained increase in platelet count were observed. Disease progression with a sustained increase in blast cells in one patient and a transient elevation of blasts in another patient was seen. No other side effects of EPO therapy were observed. These results suggest that anemic MDS patients with low serum EPO levels and relatively spared effective erythropoiesis as measured by ferrokinetic studies may be the best candidates for treatment with recombinant human EPO.

Key words

Myelodysplastic syndrome rh-Erythropoietin Ferrokinetic effects 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Aoki I, Higashi K, Homori M, Chikazawa H, Ishikawa K (1990) Responsiveness of bone marrow erythropoietic stem cells (CFU-E and BFU-E) to recombinant human erythropoietin (rh-Ep) in vitro in aplastic anemia and myelodysplastic syndrome. Am J Hematol 35: 6–12PubMedGoogle Scholar
  2. 2.
    Bennett JM, Catovsky D, Daniel HT, Galton DAG, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51: 189–199PubMedGoogle Scholar
  3. 3.
    Boogaerts MA, Nelissen V, Roelant C, Goossens W (1983) Blood neutrophil function in primary myelodysplastic syndromes. Br J Haematol 55: 217–227PubMedGoogle Scholar
  4. 4.
    Bowen DT, Jacobs A, Mary P, Cotes, Lewis TC (1990) Serum erythropoietin and erythropoiesis in patients with myelodys-plastic syndromes. Eur J Haematol 44: 30–32PubMedGoogle Scholar
  5. 5.
    Bowen D, Culligan D, Jacobs A (1991) The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin. Br J Haematol 77: 419–423PubMedGoogle Scholar
  6. 6.
    Dessypris EN, Krantz SB (1984) Effect of pure erythropoietin on DNA-synthesis by human marrow day-15 erythroid burst-forming units in short-term liquid culture. Br J Haematol 56: 295–306PubMedGoogle Scholar
  7. 7.
    Dessypris EN, Gleaton JH, Armstrong OL (1987) Effect of human recombinant erythropoietin on human marrow mega-karyocyte colony formation in vitro. Br J Haematol 65: 265–269PubMedGoogle Scholar
  8. 8.
    Dessypris EN, Graber SE, Krantz SB, Stone WJ (1988) Effects of recombinant erythropoietin on the concentration and cycling status of human marrow hematopoietic progenitor cells in vivo. Blood 72: 2060–2062PubMedGoogle Scholar
  9. 9.
    Dormer P, Hershko C, Wilmanns W (1987) Mechanisms and prognostic value of cell kinetics in the myelodysplastic syndromes. Br J Haematol 67: 147–152PubMedGoogle Scholar
  10. 10.
    Egrie JC, Cotes PM, Lane J, Gaines Das RE, Tan RC (1987) Development of radioimmunoassays for human erythropoietin using recombinant erythropoietin as tracer and immunogen. J Immunol Methods 99: 235–241PubMedGoogle Scholar
  11. 11.
    Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW (1987) Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase-I and -II clinical trial. N Engl J Med 316: 73–78PubMedGoogle Scholar
  12. 12.
    Fischl M, Galpin JE, Levine JD, Groopman JE, Henry DH, Kennedy P, Miles S, Robbins W, Starrett B, Zalusky R, Abels RI, Tsai HC, Rudnick SA (1990) Recombinant human erythro-poietin for patients with AIDS treated with Zidovudine. N Engl J Med 322: 1488–1493PubMedGoogle Scholar
  13. 13.
    Galton DAG (1986) The myelodysplastic syndromes. Scand J Haematol 36 [Suppl 45]: 11–20PubMedGoogle Scholar
  14. 14.
    Geissler K, Stockenhuber F, Kabrna E, Hinterberger W, Balcke P, Lechner K (1989) Recombinant human erythropoietin and haematopoietic progenitor cells in vivo. Blood 73: 2229PubMedGoogle Scholar
  15. 15.
    Gregory CJ, Eaves AC (1977) Human marrow cells capable of erythropoietic differentiation in vitro: definition of three erythroid colony responses. Blood 49: 855–864PubMedGoogle Scholar
  16. 16.
    Hirashima K, Bessho M, Susaki L, Miyazawa K, Nagashima M (1989) Improvement of anaemia by intravenous injection of recombinant erythropoietin in patients with myelodysplastic syndrome and aplastic anaemia. Exp Haematol 17: 385Google Scholar
  17. 17.
    International Committee for Standardization in Haematology (1971) Recommended methods for radioisotope red cell survival. Blood 38: 378–386Google Scholar
  18. 18.
    Jacobs A (1985) Myelodysplastic syndromes: pathogenesis, functional abnormalities and clinical implications. J Clin Pathol 38: 1201–1217PubMedGoogle Scholar
  19. 19.
    Jacobs A, Janowska-Wieczorek A, Caro J, Bowen DT, Lewis T (1989) Circulating erythropoietin in patients with myelodys-plastic syndromes. Br J Haematol 73: 36–39PubMedGoogle Scholar
  20. 20.
    Kannourakis G, Johnson GR (1988) Fractionation of subsets of BFU-E from normal human bone marrow: responsiveness to erythropoietin, human placental-conditioned medium, or granulocyte macrophage colony-stimulating factor. Blood 71: 758–765PubMedGoogle Scholar
  21. 21.
    Ludwig H, Fritz E, Kotzmann H, Höcker P, Gisslinger H, Barnas U (1990) Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322: 1693–1699PubMedGoogle Scholar
  22. 22.
    Means RT, Olsen NJ, Krantz SB, Dessypris EN, Graber SE, Stone WJ, O'Neil VL, Pincus T (1989) Treatment of the anemia of rheumatoid arthritis with recombinant human erythropoietin: clinical and in vitro studies. Arthritis Rheum 32: 638–642PubMedGoogle Scholar
  23. 23.
    Mitjavila MT, Villeval JL, Cramer P, Henri A, Gasson J, Krystal G, Tulliez M, Berger R, Breton-Gorius J, Vainchenker W (1987) Effects of granulocyte-macrophage colony-stimulating factor and erythropoietin on leukemic erythroid colony formation in human early erythroblastic leukemias. Blood 70: 965–973PubMedGoogle Scholar
  24. 24.
    Motoji T, Hoshino S, Ueda M, Takanashi M, Masuda M, Nakayama K, Oshimi K, Mizoguchi H (1990) Enhanced growth of clonogenic cells from acute myeloblastic leukaemia by erythropoietin. Br J Haematol 75: 60–67PubMedGoogle Scholar
  25. 25.
    Nishi N, Nakahata T, Koike K, Takagi M, Nagunuma K, Aka-bane T (1990) Induction of mixed erythroid-megakaryocyte colonies and bipotential blast cell colonies by recombinant human erythropoietin in serum-free culture. Blood 76: 1330–1335PubMedGoogle Scholar
  26. 26.
    Ohyashiki K, Fujieda H, Iwabuchi A, Ohyashiki JH, Toyama K (1990) In vitro cytogenetic effects of recombinant human hematopoietic growth factors on cells derived from myelodys-plastic syndromes. Cancer Genet Cytogenet 48: 169–178PubMedGoogle Scholar
  27. 27.
    Oster W, Herrmann F, Gamm H, Zeile G, Lindemann A, Muller G, Brune T, Kraemer H, Mertelsmann R (1990) Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. J Clin Oncol 8: 956–962PubMedGoogle Scholar
  28. 28.
    Ricketts C, Jacobs A, Cavill I (1975) Ferrokinetics and erythropoiesis in man: the measurement of effective erythropoiesis, ineffective erythropoiesis and red cell life span using59Fe. Br J Haematol 31: 65–75PubMedGoogle Scholar
  29. 29.
    Roodman GD, Bird A, Hutzler D, Montgomery W (1987) Tumor necrosis factor-alpha and haematopoietic progenitors: effects of tumor necrosis factor on the growth of erythroid progenitors CFU-E and BFU-E and the haematopoietic cell lines K 562, HL 60, and HEL cells. Exp Haematol 15: 928Google Scholar
  30. 30.
    Schouten HC, Vellenga E, van Rhenen DJ, de Wolf DJ, Coppens PJW, Blijham GH (1991) Recombinant human erythropoietin in patients with myelodysplastic syndromes. Leukemia 5: 432–436PubMedGoogle Scholar
  31. 31.
    Stebler C, Tichelli A, Dazzi H, Gratwohl A, Nissen C, Speck B (1990) High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: a pilot study. Exp Haematol 18: 1204–1208Google Scholar
  32. 32.
    Urabe A, Kitamura T, Takaku F (1988) Clinical application of erythropoietin. Acta Haematol (Japonica) 51: 1355–1359Google Scholar
  33. 33.
    Vadhan-Raj S, Hittelman WN, Lepe-Zuniga JL, Gutterman JU, Broxmeyer HE (1990) Regulation of endogenous erythropoietin levels in anemia associated with myelodysplastic syndromes. N Engl J Med 75: 1749–1750Google Scholar
  34. 34.
    Verhoef G, De Wolf-Peeters C, Kerim S, Van De Broeck J, Mecucci C, Van Den Berghe H, Boogaerts M (1991) Update on the prognostic implication of morphology, histology and karyotype in primary myelodysplastic syndromes. Hematol Pathol 5: 163–175PubMedGoogle Scholar
  35. 35.
    Witte T, Zwaan F, Hermans J, Vernant J, Kolb H, Vossen J, Lönqvist B, Beelen D, Ferrant A, Gmur J, Liu Yin J, Troussard X, Cahn J, Van Lint M, Gratwohl A (1990) Allogeneic bone marrow transplantation for secondary leukaemia and myelo-dysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol 74: 151–155PubMedGoogle Scholar
  36. 36.
    Zoumbos N, Symeonidis A, Kourakli A, Katevas P, Matsouka P, Perraki M, Geogoulias V (1991) Increased levels of soluble interleukin-2 receptors and tumor necrosis factor in serum of patients with myelodysplastic syndromes. Blood 77: 413–414PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • G. E. G. Verhoef
    • 1
  • P. Zachée
    • 1
  • A. Ferrant
    • 2
  • H. Demuynck
    • 1
  • D. Selleslag
    • 1
  • L. Van Hove
    • 1
  • F. Deckers
    • 3
  • M. A. Boogaerts
    • 1
  1. 1.Department of HematologyUniversity Hospital GasthuisbergLeuven
  2. 2.Department of HematologyCliniques Universitaires St-LucBelgium
  3. 3.CilagBrusselsBelgium

Personalised recommendations